Innovation Portfolio Management and Innovation Strategy and Business Process Expert @ (November 2019 - January 2022)
Director R and D Business Incubation @ (June 2014 - December 2019)
Director R and D New Business Development - Cameleo Venture @ (July 2012 - June 2014)
Disease Area Director Sepsis @ (November 2011 - September 2012)
Program Director @ (January 2010 - November 2011)
Senior Director and Program Manager @ (October 2007 - January 2010)
Director of Technology Strategy @ (June 2007 - January 2009)
Senior Scientist @ (February 2000 - June 2007)
EU-Fellow Science and Technology @ (January 1998 - December 1999)
PhD student and aio @ (January 1993 - January 1997)
Henk Stapert Education
University of Twente
PhD (Chemistry, Biomaterials, Polymers)
1993-1997
University of Twente
Ir (Chemical Technology, Biomedical Technology)
1987-1993
Henk Stapert Skills
Biomedical Engineering
Biotechnology
CAPA
Commercialization
Cross-functional Team Leadership
Design Control
FDA
Hardware Diagnostics
ISO 13485
Innovation Management
Life Sciences
Lifesciences
Management
Medical Devices
Medical Imaging
Microbiology
Oncology
Product Development
Product Launch
Product Management
R&D
Research and Development (R&D)
Strategy
Validation
Development
Technology
Public Speaking
Systems Engineering
Business Development
Business Analysis
Cross Functional Team Leadership
Research
Research Projects
Research and Development R&d
Research and Development
Henk Stapert Summary
Henk Stapert, based in Eindhoven, NB, NL, is currently a Chief Technology Officer at smartQare BV. Henk Stapert brings experience from previous roles at ShanX Medtech BV and Philips. Henk Stapert holds a 1993 - 1997 PhD in Chemistry, Biomaterials, Polymers @ University of Twente. With a robust skill set that includes Biomedical Engineering, Biotechnology, CAPA, Commercialization, Cross-functional Team Leadership and more. Henk Stapert has 2 emails and 1 mobile phone numbers on RocketReach.
Looking for a different Henk Stapert?
Find contact details for 700 million professionals.